ClinicalTrials.gg

Program

HRS-4029

A development code.

Its studies are mostly in Ischemic Stroke, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Jul 28, 20262 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine22 open or runningphase 2since Jul 28, 2026Mar 25, 2025Apr 2027phase 2 · NCT07739160
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-4029, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 25, 2025First study: phase 1 study in Ischemic StrokeFirst studyNCT06905314 · 55 planned · China
  2. Jul 28, 2026Phase 2 study in Ischemic StrokePhase 2 reachedNCT07739160 · 340 planned · China

Ahead

  1. Apr 2027Primary completion: phase 2 study in Ischemic StrokeNCT07739160

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07739160Ischemic Stroke · China2RecruitingApr 2027340
NCT06905314Ischemic Stroke · China1Not yet recruitingOct 202555

How it is read

Names in the registry

  • “HRS-4029”, 2 entries

Codes read as this program: HRS4029.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.